Anavex Life Sciences Corp

(NASDAQ:AVXL)

Latest On Anavex Life Sciences Corp (AVXL):

Date/Time Type Description Signal Details
2023-05-09 09:59 ESTNewsAnavex Life Sciences GAAP EPS of -$0.17 beats by $0.01N/A
2023-05-09 09:59 ESTNewsAnavex Life Sciences Corp. (AVXL) Q2 2023 Earnings Call TranscriptN/A
2023-05-08 21:26 ESTNewsAnavex Life Sciences Q2 2023 Earnings PreviewN/A
2023-05-04 09:38 ESTNewsAnavex And The Antioxidant Treatment Of Alzheimer's DiseaseN/A
2023-04-06 10:52 ESTNewsBiogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of RevisionsN/A
2023-03-31 01:41 ESTNewsAnavex gains on long-term data for Parkinson’s disease therapyN/A
2023-03-16 14:51 ESTNewsBuy Anavex For Its Likely Positive Alzheimer's Disease DataN/A
2023-03-08 22:50 ESTNewsAnavex: Many Questions Answered, A Few Still Left, But Things Are Progressing WellN/A
2023-02-09 22:02 ESTNewsAnavex Life Sciences: Recent Earnings Reveals Strong Cash Position To Get ANAVEX 2-73 Through FDAN/A
2023-02-07 16:44 ESTNewsAnavex Life Sciences GAAP EPS of -$0.17 beats by $0.02N/A
2023-02-07 16:44 ESTNewsAnavex Life Sciences Corp. (AVXL) Q1 2023 Earnings Call TranscriptN/A
2023-02-07 16:43 ESTNewsAnavex hits two-month high after Q1 FY23 resultsN/A
2023-02-06 15:12 ESTNewsAnavex Life Sciences Q1 2023 Earnings PreviewN/A
2023-02-02 15:43 ESTNewsAnavex gains as trial for Rett syndrome candidate exceeds enrollment targetN/A
2023-01-31 00:23 ESTNewsApproval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi ApprovedN/A
2023-01-17 17:52 ESTNewsAnavex: Drug Treatments For Early Alzheimer's DiseaseN/A
2023-01-12 19:56 ESTNewsAnavex: Despite Positive Spin, No Clarity On AnomaliesN/A
2023-01-06 22:58 ESTNewsLilly, Anavex, other Alzheimer's drug developers rise modestly on Biogen lecanemab approvalN/A
2022-12-21 18:35 ESTNewsHow Well Does Anavex's New Alzheimer's Drug Compare Against Biogen's New Drug?N/A
2022-12-10 07:25 ESTNewsAnavex: A Thorough Approach To The DataN/A
2022-12-08 04:30 ESTNewsAnavex Life Sciences stock slides as downgraded to neutral at Cantor FitzgeraldN/A
2022-12-06 15:57 ESTNewsAnavex Life Sciences: The Little Company That DidN/A
2022-12-04 07:23 ESTNewsAnavex's Alzheimer's Results Leave Much To Be DesiredN/A
2022-12-02 19:33 ESTNewsAnavex surges 40% as drug improves cognitive function in Alzheimer's patients, meets trial's goalsN/A
2022-12-02 19:32 ESTNewsJones sees Anavex as 'clear M&A target' after Alzheimer's drug's trial successN/A
2022-11-30 14:05 ESTNewsAnavex Life Sciences: Market Unimpressed As Major Alzheimer's Data Readout ArrivesN/A
2022-11-29 21:24 ESTNewsAnavex defended at Cantor on prospects for rare disease therapyN/A
2022-11-29 02:23 ESTNewsAnavex Life Sciences Corp. (AVXL) Q4 2022 Earnings Call TranscriptN/A
2022-11-29 02:23 ESTNewsAnavex drops 16% after fiscal 2022 updateN/A
2022-11-28 08:22 ESTNewsAnavex Life Sciences GAAP EPS of -$0.18 misses by $0.01N/A
2022-11-08 08:37 ESTNewsAnavex Life Sciences At A Pivotal MomentN/A
2022-11-07 15:31 ESTNewsAnavex therapy for Fragile X syndrome gets FDA orphan drug statusN/A
2022-09-29 23:01 ESTNewsBiogen, Eisai cool off after massive run-up following lecanemab Alzheimer's dataN/A
2022-09-21 22:13 ESTNewsAnavex wins new U.S. patent for lead candidateN/A
2022-09-19 19:30 ESTNewsAnavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease DementiaN/A
2022-09-08 07:56 ESTNewsAnavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's DiseaseN/A
2022-08-11 23:27 ESTNewsAnavex And The Debunking Of The Amyloid HypothesisN/A
2022-08-10 12:59 ESTNewsAnavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q3 2022 Results - Earnings Call TranscriptN/A
2022-08-09 19:18 ESTNewsAnavex Life Sciences GAAP EPS of -$0.16 beats by $0.01N/A
2022-08-08 20:39 ESTNewsAnavex Life Sciences Q3 2022 Earnings PreviewN/A
2022-08-01 22:33 ESTNewsAnavex gains on the effect of Alzheimer’s drug on genesN/A
2022-06-24 04:00 ESTNewsAnavex gains as Berenberg launches coverage with Buy ratingN/A
2022-06-02 22:17 ESTNewsAnavex's Blarcamesine: Why It May Treat Alzheimer's DiseaseN/A
2022-05-31 18:54 ESTNewsAnavex: Increasing Shareholder Value Against All OddsN/A
2022-05-11 00:41 ESTNewsAnavex Life Sciences GAAP EPS of -$0.14 beats by $0.03N/A
2022-05-11 00:40 ESTNewsAnavex Life Sciences GAAP EPS of -$0.14 beats by $0.05N/A
2022-05-11 00:40 ESTNewsAnavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q2 2022 Results - Earnings Call TranscriptN/A
2022-05-10 02:36 ESTNewsAnavex Life Sciences Q2 2022 Earnings PreviewN/A
2022-03-24 04:50 ESTNewsAnavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's DiseaseN/A
2022-03-15 17:38 ESTNewsAnavex posts mid-stage biomarker data for lead candidateN/A

About Anavex Life Sciences Corp (AVXL):

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

AVXL Quotes by TradingView

See Advanced Chart

General

  • Name Anavex Life Sciences Corp
  • Symbol AVXL
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 20
  • Last Split Factor1:4
  • Last Split Date2015-10-07
  • Fiscal Year EndSeptember
  • IPO Date2006-08-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.anavex.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 23.64
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.50
  • Next Year EPS Estimate -$0.55
  • Next Quarter EPS Estimate -$0.11
  • Return on Assets -41%
  • Return on Equity -76%
  • Earnings Per Share -$0.60
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.03 billion
  • Analyst Target Price $15.2
  • Book Value Per Share $0.69
View More

Share Statistics

  • Shares Outstanding 69.49 million
  • Shares Float 67.14 million
  • % Held by Insiders 363%
  • % Held by Institutions 19.19%
  • Shares Short 3.96 million
  • Shares Short Prior Month 4.01 million
  • Short Ratio 0.47
  • Short % of Float 6%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 0.63
  • 52 Week High $16.39
  • 52 Week Low $2.23
  • 50 Day Moving Average 12.26
  • 200 Day Moving Average 6.92
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Anavex Life Sciences Corp (AVXL) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Anavex Life Sciences Corp (AVXL) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-11$N/A-$0.12-$0.120%
2020-09-302020-12-28$N/A-$0.10-$0.1323.08%
2020-06-302020-08-06$N/A-$0.11-$0.1418.52%
2020-03-312020-05-07$N/A-$0.12-$0.1623.42%
2019-12-312020-02-06$N/A-$0.12-$0.120%
2019-09-302019-12-16$N/A-$0.07-$0.1552.4%
2019-06-302019-08-07$N/A-$0.14-$0.1715.71%
2019-03-312019-05-08$N/A-$0.17-$0.14-21.43%
2018-12-312019-02-07$N/A-$0.16-$0.13-23.08%
2018-09-302018-12-12$N/A-$0.13-$0.11-18.18%
2018-06-302018-08-09$N/A-$0.06-$0.1041.92%
2018-03-312018-05-10$N/A-$0.11-$0.10-10%
2017-12-312018-02-07$N/A-$0.09
2017-09-302017-12-11$N/A-$0.12-$0.10-20%
2017-06-302017-08-07$N/A-$0.09-$0.091.33%
2017-03-312017-05-10$N/A-$0.04-$0.0955.56%
2016-12-312017-02-07$N/A-$0.08-$0.1127.27%
2016-09-302016-12-12$N/A-$0.18
2016-06-302016-08-11$N/A-$0.06-$0.0924.59%
2016-03-312016-05-11$N/A-$0.06-$0.1660.81%
2015-12-312016-02-08$N/A-$0.12-$0.1414.29%
2015-09-302015-12-29$N/A-$0.21-$0.06-250%
2015-06-302015-08-17$N/A-$0.22
2015-03-312015-05-15$N/A-$0.12
2014-12-312015-02-18$N/A-$0.06
2014-09-302014-12-29$N/A-$0.20-$0.200%
2014-06-302014-08-13$N/A-$0.10
2014-03-312014-05-28$N/A-$0.11
2013-12-312014-02-26$N/A$0.03
2013-09-302013-09-30$N/A-$0.40
2013-06-302013-06-30$N/A-$0.02
2013-03-312013-03-31$N/A-$0.01
2012-12-312012-12-31$N/A-$0.06
2012-09-302012-09-30$N/A-$0.10
2012-06-302012-06-30$N/A-$0.64
2012-03-312012-03-31$N/A-$0.13
2011-12-312011-12-31$N/A-$0.33
2011-09-302011-09-30-$0.23
2011-06-302011-06-30$N/A-$0.25
2011-03-312011-03-31-$0.31
2010-12-312010-12-31-$0.31
2010-09-302010-09-30-$0.52
2010-06-302010-06-30-$0.37
2010-03-312010-03-31-$0.33
2009-12-312009-12-31-$0.09
2009-09-302009-09-30-$0.36
2009-06-302009-06-30-$0.27
2009-03-312009-03-31-$0.25
2008-12-312008-12-31-$0.19
2008-09-302008-09-30-$0.42
2008-06-302008-06-30-$0.34
2008-03-312008-03-31-$0.14
2007-12-312007-12-31-$0.19
2007-09-302007-09-30-$0.24
2007-06-302007-06-30-$0.05
2007-03-312007-03-31-$0.04
2006-12-312006-12-31$-0.00
2006-09-302006-09-30$-0.00

Anavex Life Sciences Corp (AVXL) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Anavex Life Sciences Corp (AVXL) Chart:

Anavex Life Sciences Corp (AVXL) News:

Below you will find a list of latest news for Anavex Life Sciences Corp (AVXL) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Anavex Life Sciences Corp (AVXL) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-07-1711.36CALL4 5648.31TRUE1.360
2026-07-1720.38CALL6 22145.13TRUE0.380
2026-07-1730.05CALL27 672184.09FALSE0.050
2026-07-1740CALL0 820321.68FALSE00
2026-07-1750CALL0 686416.78FALSE00
2026-07-1760CALL0 1280736.92FALSE00
2026-07-1770CALL0 796548.72FALSE00
2026-07-1780CALL0 5577598.21FALSE00
2026-07-17100CALL0 476678.01FALSE00
2026-07-1710PUT0 01368.23FALSE00
2026-07-1720.03PUT0 257146.65FALSE00
2026-07-1730.56PUT0 732150.15TRUE00
2026-07-1740PUT0 13425.25TRUE00
2026-07-1750PUT0 8362.4TRUE00
2026-07-1760PUT0 0430.61TRUE00
2026-07-1770PUT0 0486.43TRUE00
2026-07-1780PUT0 0533.64TRUE00
2026-07-17100PUT0 0610.6TRUE00
2026-08-2110CALL0 0168.57TRUE00
2026-08-2120CALL0 3131.55TRUE00
2026-08-2130.1CALL29 58993.86FALSE-0.05-0.33
2026-08-2140.05CALL81 94179.22FALSE00
2026-08-2150CALL0 0207FALSE00
2026-08-2160CALL0 5179.02FALSE00
2026-08-2110PUT0 0362.37FALSE00
2026-08-2120.1PUT0 2084.15FALSE00
2026-08-2130.66PUT0 938.61TRUE00
2026-08-2140PUT0 1110.52TRUE00
2026-08-2150PUT0 0127.39TRUE00
2026-08-2160PUT0 0151.83TRUE00
2026-10-1610CALL0 149.37TRUE00
2026-10-1620CALL0 1144.88TRUE00
2026-10-1630.24CALL5 173114.93FALSE0.240
2026-10-1640CALL0 45159.73FALSE00
2026-10-1650.07CALL36 49598FALSE0.070
2026-10-1660CALL0 8206.09FALSE00
2026-10-1670CALL0 4204.55FALSE00
2026-10-1680CALL0 151177.04FALSE00
2026-10-1690CALL0 2561.23FALSE00
2026-10-1610PUT0 0308.23FALSE00
2026-10-1620.22PUT19 63687.33FALSE0.020.1
2026-10-1630PUT0 1171.21TRUE00
2026-10-1640PUT0 2294.48TRUE00
2026-10-1650PUT0 4110.01TRUE00
2026-10-1660PUT0 1128.57TRUE00
2026-10-1670PUT0 0120.88TRUE00
2026-10-1685.62PUT1 2133.15TRUE5.620
2026-10-1690PUT0 0143.93TRUE00
2027-01-1510CALL0 4133.02TRUE00
2027-01-1520CALL0 15101.9TRUE00
2027-01-1530CALL0 1053177.55FALSE00
2027-01-1540CALL0 4089.35FALSE00
2027-01-1550CALL0 1080107.57FALSE00
2027-01-1560CALL0 42121.24FALSE00
2027-01-1570CALL0 1465105.4FALSE00
2027-01-15100CALL0 6511119.63FALSE00
2027-01-15120CALL0 1813156.3FALSE00
2027-01-15150CALL0 1776207.4FALSE00
2027-01-15170CALL0 358214.75FALSE00
2027-01-15200.1CALL1 2805224.05FALSE-0.1-0.5
2027-01-15220.2CALL0 350229.38FALSE00
2027-01-15250CALL0 487176.31FALSE00
2027-01-15270CALL0 173180.12FALSE00
2027-01-1510PUT0 0177.19FALSE00
2027-01-1520PUT0 120140.78FALSE00
2027-01-1530PUT0 481111.09TRUE00
2027-01-1540PUT0 4153.75TRUE00
2027-01-1550PUT0 235131.81TRUE00
2027-01-1560PUT0 0130.75TRUE00
2027-01-1570PUT0 97110.67TRUE00
2027-01-15100PUT0 42121.53TRUE00
2027-01-15120PUT0 0151.37TRUE00
2027-01-15150PUT0 0151.05TRUE00
2027-01-15170PUT0 0160.38TRUE00
2027-01-15200PUT0 0172.68TRUE00
2027-01-15220PUT0 0180.01TRUE00
2027-01-15250PUT0 0189.96TRUE00
2027-01-15270PUT0 0196.01TRUE00
2028-01-2130.96CALL0 5820FALSE00
2028-01-2150.62CALL33 305100.64FALSE-0.17-0.22
2028-01-2170CALL0 8289.48FALSE00
2028-01-21100CALL0 380182.29FALSE00
2028-01-21120CALL0 1580FALSE00
2028-01-21150CALL0 20FALSE00
2028-01-21170CALL0 84158.61FALSE00
2028-01-2131.15PUT1 30587.93TRUE1.150
2028-01-2150PUT0 21580.72TRUE00
2028-01-2170PUT0 292104.98TRUE00
2028-01-21100PUT0 2887.04TRUE00
2028-01-21120PUT0 2096.79TRUE00
2028-01-21150PUT0 28109.05TRUE00
2028-01-21170PUT0 3116.12TRUE00

Latest AVXL Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST200$7.57
Jun 13, 2022 7:59 PM EST58$7.56
Jun 13, 2022 7:59 PM EST1$7.57
Jun 13, 2022 7:59 PM EST100$7.57
Jun 13, 2022 7:59 PM EST29$7.56

Anavex Life Sciences Corp (AVXL) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000712/0001731122-20-000712-index.htm
2017-06-09UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314052/000000000017020197/0000000000-17-020197-index.htm
2019-07-11UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1314052/000000000019011025/0000000000-19-011025-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000083423720008231/0000834237-20-008231-index.htm
2020-03-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000083423720009195/0000834237-20-009195-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571818000242/0000905718-18-000242-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571819000231/0000905718-19-000231-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1314052/000090571820000234/0000905718-20-000234-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000121390019010249/0001213900-19-010249-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019010601/0001213900-19-010601-index.htm
2019-06-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019010604/0001213900-19-010604-index.htm
2019-07-03S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314052/000121390019012072/0001213900-19-012072-index.htm
2019-07-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314052/000121390019012578/0001213900-19-012578-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019014791/0001213900-19-014791-index.htm
2019-09-13S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1314052/000121390019018007/0001213900-19-018007-index.htm
2019-09-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000121390019018012/0001213900-19-018012-index.htm
2019-09-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018023/0001213900-19-018023-index.htm
2019-09-16AWAmendment Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018132/0001213900-19-018132-index.htm
2019-09-17POS AMPost-Effective amendments for registration statementhttps://www.sec.gov/Archives/edgar/data/1314052/000121390019018310/0001213900-19-018310-index.htm
2017-06-09CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1314052/000161577417003075/0001615774-17-003075-index.htm
2017-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577417004118/0001615774-17-004118-index.htm
2017-08-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004281/0001615774-17-004281-index.htm
2017-08-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004290/0001615774-17-004290-index.htm
2017-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004399/0001615774-17-004399-index.htm
2017-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004574/0001615774-17-004574-index.htm
2017-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004587/0001615774-17-004587-index.htm
2017-08-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004745/0001615774-17-004745-index.htm
2017-08-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004809/0001615774-17-004809-index.htm
2017-08-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004886/0001615774-17-004886-index.htm
2017-09-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004918/0001615774-17-004918-index.htm
2017-09-07424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1314052/000161577417004964/0001615774-17-004964-index.htm
2017-09-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417004994/0001615774-17-004994-index.htm
2017-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005014/0001615774-17-005014-index.htm
2017-09-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005088/0001615774-17-005088-index.htm
2017-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005183/0001615774-17-005183-index.htm
2017-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005226/0001615774-17-005226-index.htm
2017-09-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005351/0001615774-17-005351-index.htm
2017-09-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005440/0001615774-17-005440-index.htm
2017-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005508/0001615774-17-005508-index.htm
2017-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005604/0001615774-17-005604-index.htm
2017-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005634/0001615774-17-005634-index.htm
2017-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005731/0001615774-17-005731-index.htm
2017-10-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005767/0001615774-17-005767-index.htm
2017-10-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005807/0001615774-17-005807-index.htm
2017-10-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005861/0001615774-17-005861-index.htm
2017-10-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417005929/0001615774-17-005929-index.htm
2017-12-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577417007272/0001615774-17-007272-index.htm
2017-12-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417007355/0001615774-17-007355-index.htm
2017-12-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577417007357/0001615774-17-007357-index.htm
2018-02-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418000934/0001615774-18-000934-index.htm
2018-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001587/0001615774-18-001587-index.htm
2018-03-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001629/0001615774-18-001629-index.htm
2018-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001650/0001615774-18-001650-index.htm
2018-03-08DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001673/0001615774-18-001673-index.htm
2018-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001701/0001615774-18-001701-index.htm
2018-03-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418001744/0001615774-18-001744-index.htm
2018-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418002786/0001615774-18-002786-index.htm
2018-04-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418002846/0001615774-18-002846-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418003574/0001615774-18-003574-index.htm
2018-05-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418004019/0001615774-18-004019-index.htm
2018-05-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418004023/0001615774-18-004023-index.htm
2018-07-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418006278/0001615774-18-006278-index.htm
2018-07-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577418006280/0001615774-18-006280-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577418007805/0001615774-18-007805-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010436/0001615774-18-010436-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010439/0001615774-18-010439-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010441/0001615774-18-010441-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010443/0001615774-18-010443-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010445/0001615774-18-010445-index.htm
2018-10-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010447/0001615774-18-010447-index.htm
2018-10-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577418010620/0001615774-18-010620-index.htm
2018-12-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577418014328/0001615774-18-014328-index.htm
2019-01-2510-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000161577419001031/0001615774-19-001031-index.htm
2019-01-31PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419001498/0001615774-19-001498-index.htm
2019-02-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419002057/0001615774-19-002057-index.htm
2019-02-11DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419002242/0001615774-19-002242-index.htm
2019-03-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419004136/0001615774-19-004136-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577419004139/0001615774-19-004139-index.htm
2019-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000161577419005452/0001615774-19-005452-index.htm
2019-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000161577419007213/0001615774-19-007213-index.htm
2019-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/0001615774-19-007324-index.htm
2019-12-1610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1314052/000173112219000784/0001731122-19-000784-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000018/0001731122-20-000018-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000019/0001731122-20-000019-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000020/0001731122-20-000020-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000021/0001731122-20-000021-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000022/0001731122-20-000022-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000023/0001731122-20-000023-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000024/0001731122-20-000024-index.htm
2020-02-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000103/0001731122-20-000103-index.htm
2020-02-20DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000195/0001731122-20-000195-index.htm
2020-03-23DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000289/0001731122-20-000289-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000360/0001731122-20-000360-index.htm
2020-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000430/0001731122-20-000430-index.htm
2020-05-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000431/0001731122-20-000431-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000432/0001731122-20-000432-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000447/0001731122-20-000447-index.htm
2020-07-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000711/0001731122-20-000711-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220000712/0001731122-20-000712-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1314052/000173112220000807/0001731122-20-000807-index.htm
2020-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220001047/0001731122-20-001047-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1314052/000173112220001114/0001731122-20-001114-index.htm
2017-06-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999517001508/9999999995-17-001508-index.htm
2019-07-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999519001606/9999999995-19-001606-index.htm
2019-09-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1314052/999999999519002138/9999999995-19-002138-index.htm

Anavex Life Sciences Corp (AVXL) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Anavex Life Sciences Corp (AVXL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 363%
Institutional Ownership: 1919%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2017-08-11CHRISTOPHER U MISSLINGPresident and CEOBuy750.003.552,662.501,004,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004281/0001615774-17-004281-index.htm
2017-08-14CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.701,387.501,004,375.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004399/0001615774-17-004399-index.htm
2017-08-18CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.811,428.751,004,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004574/0001615774-17-004574-index.htm
2017-08-21CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.071,526.251,005,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004587/0001615774-17-004587-index.htm
2017-08-24CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.541,702.501,005,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004745/0001615774-17-004745-index.htm
2017-08-28CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.441,665.001,005,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004809/0001615774-17-004809-index.htm
2017-08-31CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.481,680.001,006,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004886/0001615774-17-004886-index.htm
2017-09-05CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.901,837.501,006,625.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004918/0001615774-17-004918-index.htm
2017-09-07CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.761,785.001,007,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417004994/0001615774-17-004994-index.htm
2017-09-11CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.811,803.751,007,375.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005014/0001615774-17-005014-index.htm
2017-09-14CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.581,717.501,007,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005088/0001615774-17-005088-index.htm
2017-09-18CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.401,650.001,008,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005183/0001615774-17-005183-index.htm
2017-09-20CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.231,586.251,008,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005226/0001615774-17-005226-index.htm
2017-09-26CHRISTOPHER U MISSLINGPresident and CEOBuy375.003.881,455.001,008,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005351/0001615774-17-005351-index.htm
2017-09-28CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.211,578.751,009,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005440/0001615774-17-005440-index.htm
2017-10-02CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.201,575.001,009,625.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005508/0001615774-17-005508-index.htm
2017-10-05CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.301,612.501,010,000.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005604/0001615774-17-005604-index.htm
2017-10-13CHRISTOPHER U MISSLINGPresident and CEOBuy750.004.223,165.001,010,750.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005731/0001615774-17-005731-index.htm
2017-10-17CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.271,601.251,011,125.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005767/0001615774-17-005767-index.htm
2017-10-19CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.491,683.751,011,500.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005807/0001615774-17-005807-index.htm
2017-10-24CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.921,845.001,011,875.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005861/0001615774-17-005861-index.htm
2017-10-25CHRISTOPHER U MISSLINGPresident and CEOBuy375.004.391,646.251,012,250.00https://www.sec.gov/Archives/edgar/data/1314052/000161577417005929/0001615774-17-005929-index.htm
2018-03-02CHRISTOPHER U MISSLINGDirector, President & CEOBuy1,650.002.413,976.501,013,900.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001587/0001615774-18-001587-index.htm
2018-03-05CHRISTOPHER U MISSLINGPresident and CEOBuy1,500.002.633,945.001,015,400.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001629/0001615774-18-001629-index.htm
2018-03-06CHRISTOPHER U MISSLINGPresident and CEOBuy1,450.002.733,958.501,016,850.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001650/0001615774-18-001650-index.htm
2018-03-07CHRISTOPHER U MISSLINGPresident and CEOBuy1,360.002.923,971.201,018,210.00https://www.sec.gov/Archives/edgar/data/1314052/000161577418001744/0001615774-18-001744-index.htm